1,2,3,4-四氢-6-羟基-2-萘羧酸 | 53567-96-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1,2,3,4-四氢-6-羟基-2-萘羧酸
• 英文名称: 6-hydroxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid
• 英文别名: 1,2,3,4-tetrahydro-6-n-hydroxynaphthalene-2-carboxylic acid
• CAS: 53567-96-7
• 化学式: C₁₁H₁₂O₃
• mdl: MFCD08669473
• 分子量: 192.214
• InChiKey: RRYULKFLVMRGPW-UHFFFAOYSA-N

物化性质

• 熔点：
  137-138 °C(Solv: ethyl acetate (141-78-6); ligroine (8032-32-4))
• 沸点：
  422.7±45.0 °C(Predicted)
• 密度：
  1.308±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2918290000

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢-6-羟基-2-萘羧酸 在 咪唑 、 lithium aluminium tetrahydride 、 正丁基锂 、 硼烷四氢呋喃络合物 、 硫酸 、 copper diacetate 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 42.0h， 生成 methyl 2-((tert-butyldimethylsilyloxy)(6-phenoxy-1,2,3,4-tetrahydronaphthalen-2-yl)methyl)oxazole-5-carboxylate
  参考文献：
  名称：

  Reversible Competitive α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Containing Additional Conformational Constraints in the Acyl Side Chain: Orally Active, Long-Acting Analgesics

  摘要：

  A series of alpha-ketooxazoles containing conformational constraints in the C2 acyl side chain of 2 (OL-135) were examined as inhibitors of fatty acid amide hydrolase (FAAH). Only one of the two possible enantiomers displayed potent FAAH inhibition (S vs R enantiomer), and their potency is comparable or improved relative to 2, indicating that the conformational restriction in the C2 acyl side chain is achievable. A cocrystal X-ray structure of the alpha-ketoheterocycle 12 bound to a humanized variant of rat FAAH revealed its binding details, confirmed that the (S)-enantiomer is the bound active inhibitor, shed light on the origin of the enantiomeric selectivity, and confirmed that the catalytic Ser241 is covalently bound to the electrophilic carbonyl as a deprotonated hemiketal. Preliminary in vivo characterization of the inhibitors 12 and 14 is reported demonstrating that they raise brain anandamide levels following either intraperitoneal (ip) or oral (po) administration indicative of effective in vivo FAAH inhibition. Significantly, the oral administration of 12 caused dramatic accumulation of anandamide in the brain, with peak levels achieved between 1.5 and 3 h, and these elevations were maintained over 9 h. Additional studies of these two representative members of the series (12 and 14) in models of thermal hyperalgesia and neuropathic pain are reported, including the demonstration that 12 administered orally significantly attenuated mechanical (> 6 h) and cold (> 9 h) allodynia for sustained periods consistent with its long-acting effects in raising the endogenous concentration of anandamide.

  DOI：

  10.1021/jm101597x
• 作为产物：
  描述：

  6-溴-2-萘乙酸酯 在 异戊醇 、 sodium 作用下， 生成 1,2,3,4-四氢-6-羟基-2-萘羧酸
  参考文献：
  名称：

  The Hydrogenation of Hydroxynaphthoic Acids¹

  摘要：

  DOI：

  10.1021/ja01148a001

文献信息

• SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
  申请人：Calderwood Emily F.

  公开号：US20120015942A1

  公开（公告）日：2012-01-19

  This invention provides compounds of formula (I): wherein R 1a , R 1b , R 1c , R 2a , R 2b , R 2c , and R 2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  这项发明提供了式（I）的化合物： 其中R1a、R1b、R1c、R2a、R2b、R2c和R2d的取值如规范中所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明化合物的药物组合物，以及在治疗增殖性、炎症性、感染性、神经系统或心血管疾病或紊乱中使用这些组合物的方法。
• Carboxylate compounds, liquid crystal materials liquid crystal
  申请人：Mitsui Petrochemical Industries, Ltd.

  公开号：US05725798A1

  公开（公告）日：1998-03-10

  There is provided a carboxylic acid compound represented by the following formulae (I) to (IV): ##STR1## a liquid crystal material consisting of the carboxylic acid ester compound, a liquid crystal composition comprising the carboxylic acid ester compound, and a liquid crystal element using the carboxylic acid ester compound. There can be obtained advantages such as low operating temperature, high speed switching, very small electric power consumption, and high-stable contrast.

  提供了一种由下式(I)至(IV)表示的羧酸化合物：##STR1## 该羧酸酯化合物构成的液晶材料、包含该羧酸酯化合物的液晶组合物以及使用该羧酸酯化合物的液晶元件。可以得到如下优点：低工作温度、高速切换、极小的电力消耗和高稳定性对比度。
• [EN] ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING<br/>[FR] ALPHA-CÉTOHÉTÉROCYCLES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：BOGER DALE L

  公开号：WO2012106569A1

  公开（公告）日：2012-08-09

  Compounds are disclosed that are effective in inhibition of fatty acid amide hydrolase, an enzyme responsible for catabolism of endogenous cannabinoids such as anandamide. The compounds are useful as analgesic compounds and as sleep-inducing compounds, that can be orally administered, and that can have a relatively long duration of effect. Methods of preparation of the compounds are also provided. The compounds are conformationally constrained analogs of heterocyclylketones such as oxazolylketones.

  抑制脂肪酸酰胺水解酶的有效化合物已被披露，该酶负责代谢内源大麻素如阿南胺。这些化合物可用作镇痛化合物和诱导睡眠的化合物，可经口服给药，并具有相对较长的作用持续时间。还提供了这些化合物的制备方法。这些化合物是杂环酮的构象约束类似物，如噁唑基酮。
• Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3<i>R</i>)-7-Hydroxy-<i>N</i>-[(1<i>S</i>)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic)
  作者：Pauline W. Ondachi、Chad M. Kormos、Scott P. Runyon、James B. Thomas、S. Wayne Mascarella、Ann M. Decker、Hernán A. Navarro、Timothy R. Fennell、Rodney W. Snyder、F. Ivy Carroll

  DOI：10.1021/acs.jmedchem.8b00673

  日期：2018.9.13

  dine-1-yl)methyl]propyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (12) (4-Me-PDTic). Compound 12 had a Ke = 0.37 nM in a [35S]GTPγS binding assay and was 645- and >8100-fold selective for the κ relative to the μ and δ opioid receptors, respectively. Calculated log BB and CNS (central nervous system) multiparameter optimization (MPO) and low molecular weight values all predict that 12 will penetrate

  过去的研究表明，很难发现和开发有效且选择性的κ阿片受体拮抗剂，尤其是具有临床开发潜力的化合物。在这项研究中，我们对最近发现的新型四氢异喹啉κ阿片受体拮抗剂进行了结构-活性关系（SAR）研究，该拮抗剂导致（3 R）-7-羟基-N -（1 S）-2-甲基-1-[（-4-甲基哌啶-1-基）甲基]丙基} -1，2，3，4-四氢异喹啉-3-羧酰胺（12）（4-Me-PDTic）。化合物12有ķ ë = 0.37 nM的在[ 35S]GTPγS结合试验，相对于μ和δ阿片受体，对κ的选择性是645倍和> 8100倍。计算出的log BB和CNS（中枢神经系统）多参数优化（MPO）和低分子量值都预示着12个会穿透大脑，并且在大鼠体内的药代动力学研究表明，确实有12个会穿透大脑。
• Synthesis and structure-activity study of protease inhibitors. IV. Amidinonaphthols and related acyl derivatives.
  作者：TAKUO AOYAMA、TOSHIYUKI OKUTOME、TOYOO NAKAYAMA、TAKASHI YAEGASHI、RYOJI MATSUI、SHIGEKI NUNOMURA、MASATERU KURUMI、YOJIRO SAKURAI、SETSURO FUJII

  DOI：10.1248/cpb.33.1458

  日期：——

  Various amidinonaphthols and their acyl derivatives were synthesized and evaluated for inhibitory activities against trypsin, plasmin, kallikrein, thrombin, Clr and Cls, as well as against in vitro complement-mediated hemolysis. 6-Amidino-2-naphthyl 4-guanidinobenzoate (74, FUT-175) was found to have potent inhibitory activities, particularly against trypsin (IC50 : 0.02 μM), Clr (IC50 : 0.1 μM) and Cls (IC50 : 0.02 μM), and to be highly effective in inhibiting the complement-mediated hemolysis (IC50 : 0.03μM). FUT-175, furthermore, showed considerable effectiveness in the systemic Forssman shock reaction, in which involvement of the complement system as the pathogenetic factor is well established.

  合成了多种 amidinonaphthol 及其酰基衍生物，并评估了它们对胰蛋白酶、纤溶酶、激肽释放酶、凝血酶、Clr 和 Cls 以及体外补体介导溶血的抑制活性。发现 6-Amidino-2-萘基 4-胍基苯甲酸酯（74，FUT-175）具有强大的抑制活性，尤其对胰蛋白酶（IC50：0.02 μM）、Clr（IC50：0.1 μM）和 Cls（IC50：0.02 μM），并且在抑制补体介导溶血方面非常有效（IC50：0.03 μM）。此外，FUT-175 在全身性福斯曼休克反应中显示出显著的疗效，该反应中补体系统作为致病因素的作用已被充分证实。